These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15995312)

  • 1. [Pharmacologic intervention for vascular calcification].
    Segawa H; Furutani J; Miyamoto K
    Clin Calcium; 2005 Jul; 15(7):149-54. PubMed ID: 15995312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sevelamer: where are the data?
    McCarron DA
    Kidney Int; 2003 Dec; 64(6):2329; author reply 2329-30. PubMed ID: 14633168
    [No Abstract]   [Full Text] [Related]  

  • 3. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.
    Asmus HG; Braun J; Krause R; Brunkhorst R; Holzer H; Schulz W; Neumayer HH; Raggi P; Bommer J
    Nephrol Dial Transplant; 2005 Aug; 20(8):1653-61. PubMed ID: 15930018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular calcification in patients with end-stage renal disease.
    Floege J; Ketteler M
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
    Nagano N; Fukushima N
    Nihon Yakurigaku Zasshi; 2003 Nov; 122(5):443-53. PubMed ID: 14569164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of progressive vascular calcification in haemodialysis patients.
    Chertow GM; Raggi P; Chasan-Taber S; Bommer J; Holzer H; Burke SK
    Nephrol Dial Transplant; 2004 Jun; 19(6):1489-96. PubMed ID: 15102961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism and therapy of vascular calcification].
    Hara S; Yokoyama K
    Clin Calcium; 2004 May; 14(5):752-5. PubMed ID: 15577037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T; Fujii N; Ito T; Imai E
    Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
    Fukushima N; Nagano N
    Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate binder usage in kidney failure patients.
    Bleyer AJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):941-7. PubMed ID: 12783590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate binders in dialyzed patients: efficacy and cost.
    Minguela JI; Ruiz-De-Gauna R
    Pediatr Nephrol; 2004 Aug; 19(8):946; author reply 947-8. PubMed ID: 15206023
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sevelamer:hydrochloride].
    Hyodo T; Taira T; Wakai H; Takemura T; Yamamoto S; Yashida K; Baba S
    Clin Calcium; 2005 Jan; 15(1):61-70. PubMed ID: 15632474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular calcification progression -- a comparison of sevelamer and calcium-based phosphate binders.
    Raggi P
    Blood Purif; 2005; 23 Suppl 1():20-3. PubMed ID: 15832019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.